Tradipitant - Vanda Pharmaceuticals

Drug Profile

Tradipitant - Vanda Pharmaceuticals

Alternative Names: LY-686017; VLY 686

Latest Information Update: 04 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eli Lilly
  • Developer Eli Lilly; National Institute on Alcohol Abuse and Alcoholism; Vanda Pharmaceuticals
  • Class Antipruritics; Anxiolytics; Chlorobenzenes; Pyridines; Small molecules; Triazoles
  • Mechanism of Action Neurokinin 1 receptor antagonists; Substance P inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Atopic dermatitis
  • Phase II Gastroparesis; Pruritus
  • Discontinued Alcoholism; Social phobia

Most Recent Events

  • 01 Jun 2018 Phase-III clinical trials in Atopic dermatitis in USA (PO) (NCT03568331)
  • 16 Feb 2018 Interim efficacy data from a phase II trial in Pruritus presented at the 76th Annual Meeting of the American Academy of Dermatology (AAD-2018)
  • 07 Nov 2017 Vanda Pharmaceuticals plans a phase III trial for Atopic dermatitis in USA in the first half of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top